Daiichi Sankyo has been granted breakthrough status by the FDA for patritumab deruxtecan, a HER3-targeted antibody-drug conjugate (ADC) in clinical trials for lung cancer. The designation ...

In the latest recitation, Bristol-Myers Squibb is paying $800 million upfront for rights to a HER3-directed ADC from China’s SystImmune in a deal that could swell to $8.4 billion. It gives BMS ...

Now, a study by Chiu and colleagues reports that HER3 status is also an important prognostic marker of breast cancer-specific survival. ...HER3 expression was... significantly associated with ...

Essentially, this microRNA will block the production of MED1," Zhang ... Researchers also found that miR-205 regulates the ...

CS5007 (EGFR/HER3 ADC) inhibited tumor growth by blocking downstream EGFR/HER3 signaling and releasing chemotherapeutic molecules in a target-dependent manner. Its lead compound demonstrated ...

“With the other arm, one can zoom in and block a molecule such as HER3 that is expressed at a considerably lower level,” said Logtenberg. “Such a ‘dock and block’ mechanism mediated by ...